DGAP-News

Biotest AG: Monoclonal antibody BT-061 shows potential in the indication multiple sclerosis - Seite 2

BT-061 reinforces one of the body´s natural functions to prevent extreme
immune reactions. It is therefore being developed for the treatment of
diseases due to an over-reaction of the immune system. Three clinical
studies are currently underway in the lead indications rheumatoid arthritis
and chronic plaque psoriasis. Based on the data available so far, promising
efficacy and generally good safety and tolerability have been shown for
both indications.

Multiple sclerosis
Multiple sclerosis (MS) is an inflammatory autoimmune disease of the
central nervous system (CNS). MS is the most common cause of progressive
neurological disabilities in young adults. This demyelinating disease is
characterised by heterogeneous clinical manifestations, an unpredictable
course and varying prognoses.

Seven out of 100,000 people develop MS annually. The cause of the disease
remains unclear. The prevalence rate in the population is between 50 and
120 per 100,000 depending on ethnicity and geographical latitude.

Disclaimer

This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.

About Biotest

Biotest is a provider of pharmaceutical and biotherapeutic drugs as well as
reagents and systems for microbiology. With a value added chain that
extends from pre-clinical and clinical development to worldwide sales,
Biotest has specialised primarily in the areas of application of immunology
and haematology. In its Plasma Protein segment, Biotest develops and
markets immunoglobulins, coagulation factors and albumins based on human
blood plasma. These are used for diseases of the immune and haematopoietic
systems. In the Biotherapeutic segment, Biotest researches into the
clinical development of monoclonal antibodies, including in the indications
of rheumatoid arthritis and cancer of plasma cells. The products of the
Microbiological Monitoring segment are primarily used in hygiene
monitoring. Biotest has more than 1,900 employees worldwide. The preference
shares of Biotest AG are listed in the SDAX on the Frankfurt stock
exchange.

Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: [phone],
e-mail: [e-mail]
fax: [phone]

Securities´ ID No., ISIN ordinary shares: 522720, DE0005227201
Securities´ ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard/Official traded
Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart

21.10.2010 10:25 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP´s Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language:     English
Company:      Biotest AG
              Landsteinerstraße 5
              63303 Dreieich
              Deutschland
Phone:        0 61 03 - 8 01-0
Fax:          0 61 03 - 8 01-150
E-mail:       [e-mail]
Internet:     http://www.biotest.de
ISIN:         DE0005227235, DE0005227201
WKN:          522723, 522720
Indices:      SDAX
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Hamburg, Berlin, Düsseldorf, Stuttgart

End of Announcement                             DGAP News-Service

---